Exploring the link between childhood trauma and obesity in women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the relationship between childhood traumas and the deregulation of the glucocorticoid axis and inflammatory responses in obese women. It aims to compare the salivary cortisol awakening response in participants with and without a history of childhood trauma, assessed using the Childhood Trauma Questionnaire. The research will also evaluate the biological markers of stress and inflammation through various methods, including cortisol measurement in saliva, urine, and hair, as well as blood tests for pro-inflammatory cytokines. By understanding these associations, the study seeks to uncover underlying factors contributing to obesity beyond energy balance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years female BMI≥30kg/m2

Exclusion Criteria:

1. History of bariatric surgery
2. Any condition or pathology that may influence the corticotropic axis or that may modify the excretion or dosage of cortisol:

   * pregnancy, breastfeeding
   * hepatocellular insufficiency,
   * severe heart failure,
   * mild/moderate acute heart failure,
   * any psychological disorder not stabilised for at least one year
   * alcohol or drug dependence, not weaned for at least one year
   * neoplasm under treatment
3. Current infectious disease or a history of autoimmune disease (except autoimmune hypothyroidism), inflammatory disease and/or neurodegenerative disease
4. Presence of an adrenal adenoma or any known or suspected clinical adrenal or corticotropic disorder
5. Subjects with a positive diagnosis of hypercorticism or suspected hypercorticism will also be excluded: 8-hour plasma cortisol after Dexamethasone suppression test (DST) (1 mg dexamethasone taken orally at midnight the previous day) greater than 1.8 microg/100 ml (50 nmol/l)
6. antidepressant and neuroleptic treatment, benzodiazepine treatment
7. treatment(s) likely to modify the exploration of the corticotropic axis: systemic or local corticosteroid therapy or glucocorticoid infiltration for less than 6 months
8. current use of anti-inflammatory drugs or antibiotics
9. Shift worker

Where it's running

• LimogesUniversity Hospital
  Limoges, France Recruiting

Study contacts

• Study coordinator: Laurence SALLE, MD
• Email: laurence.salle@chu-limoges.fr
• Phone: 555049818

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.